Analysts think GYRE stock price could increase by 154%
Nov 08, 2025, 12:26 PM
10.15%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
5 analysts think GYRE stock price will increase by 153.59%. The current median analyst target is $18.36 compared to a current stock price of $7.24. The lowest analysts target is $16.16 and the highest analyst target is $21.00.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.